

27-28 June 2026

Al Ain Rotana Hotel, Al Ain, UAE.

CONFERENCE PROGRAM

DAY 1



27 June 2026 (Saturday)



08:30 - 05:10

08:30 - 08:40
Welcome and Orientation
Best of ASCO 2026
Conference Chair :Dr. Khalid Saeed Balaraj (SEHA Tawam, Al Ain)
Welcome Remarks: Dr. Hussam Marashi (SEHA Tawam, Al Ain)

SESSION 1: EARLY BREAST CANCER, SURGERY & PREVENTION (8:40 - 11:20)

Moderators: Dr. Emad Dawoud (SEHA Tawam, Al Ain) | Dr. Mouza Al Ameri (Tawam, Al Ain) |
Dr. Abdul Rahman Sumaida (SEHA Tawam, Al Ain) | Dr. Nouri Bennini (SEHA Tawam, Al Ain)

08:40 - 08:50	Abstract 500: First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer. Dr. Batool Mamdouh Aboud (Saudi German Hospital, Ajman)
08:50 - 09:00	Abstract 502 Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+, HER2- eBC) in the phase III lidERA BC clinical trial: Results by menopausal status. Dr. Sundus Yahya (SEHA Tawam, Al Ain)
09:00 - 09:10	Abstract LBA507: Final analysis of neoadjuvant plus adjuvant pembrolizumab in high-risk early triple-negative breast cancer (KEYNOTE-522). Dr. Aref Chehal (SSMC, Abu Dhabi)
09:10 - 09:20	Abstract 501: Baseline gene expression prognostic/predictive analysis with adjuvant ribociclib plus NSAI in early breast cancer (NATALEE). Dr. Fathi Azribi (American Hospital, Dubai)
09:20 - 09:40	The evolving role of ADCs in the management of breast cancer Supported by: AstraZeneca Dr. Saeed Rafii (Mediclinic City Hospital, Dubai)
09:40 - 09:50	Abstract LBA515: Role of neoadjuvant versus adjuvant chemotherapy, dose density and schedule in high-risk HR-positive/HER2-negative breast cancer: ADAPT/PlanB pooled analysis. Dr. Farooq Latif (Dubai Health, Dubai)
09:50 - 10:00	Abstract 1021A: Analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan plus pertuzumab (DESTINY-Breast09). Dr. Husam Marashi (SEHA Tawam, Al Ain)
10:00 - 10:10	Abstract 10515: Low-dose tamoxifen for pre-cancer and early disease: A pooled analysis by menopausal status. Dr. Avanthi Peddireddygar (NMC Speciality Hospital, Abu Dhabi)
10:10 - 10:20	LBA 514: I-SPY2.2: Neoadjuvant rilvegostomig plus trastuzumab deruxtecan in high-risk HR-positive/HER2-negative disease. Dr. Maroun El Khoury (American Hospital, Dubai)
10:20 - 10:40	CDK4/6 inhibitors: Clinical Integration in Breast Cancer Supported by Novartis Dr. Muhammad Farooq Latif (Dubai Health, Dubai)
10:40 - 11:00	From early to advanced HR+ HER2- disease: Verzenio Reshaping Breast Cancer Care Supported by Eli Lilly Dr. Dina Hamza (Dubai Hospital, Dubai)

AstraZeneca

NOVARTIS

Lilly
A MEDICINE COMPANY

*Subject to
changes

11:00 - 11:20		Coffee Break / Networking	
SESSION 2: METASTATIC BREAST CANCER (11:20 - 12:30)			
Moderators: Dr. Soni Soumian (SEHA Tawam, Al Ain) Dr. Sundus Yahya (SEHA Tawam, Al Ain) Dr. Dina Hamza (Dubai Hospital, Dubai) Dr. Nouri Bennini (SEHA Tawam, Al Ain)			
11:20 - 11:30	Abstract 1005: Efficacy and safety of tucatinib versus placebo combined with trastuzumab and pertuzumab as maintenance therapy for HER2-positive metastatic breast cancer by stratified subgroups (HER2CLIMB-05). Dr. Dorai Ramanathan (Al Zahra Hospital, Dubai)		
11:30 - 11:40	Abstract LBA1006: Giredestrant plus palbociclib versus letrozole plus palbociclib as first-line therapy in ER-positive/HER2-negative locally advanced or metastatic breast cancer: persevERA BC. Dr. Saeed Rafii (Mediclinic City Hospital, Dubai)		
11:40 - 11:50	Abstract LBA1007: First-line camizestrant for emergent ESR1 mutations in advanced breast cancer: Final PFS2 from SERENA-6. Dr. Dina Hamza (Dubai Hospital, Dubai)		
11:50 - 12:00	Abstract LBA1000: ASCENT-04: Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in previously untreated PD-L1-positive metastatic triple-negative breast cancer. Dr. Aladdin Marraoui (GICC, Abu Dhabi)		
12:00 - 12:10	Abstract 1014: Biomarker subgroup efficacy analysis of sacituzumab govitecan versus chemotherapy in first-line TNBC, ASCENT-03. Dr. Bassel Jallad (CCAD, Abu Dhabi)		
12:10 - 12:30	Post ASCO 2026 Updates: HR+/HER2- Breast Cancer Supported by Roche Dr. Saeed Rafii (Mediclinic City Hospital, Dubai)		
12:30 - 12:50	Elevating Care in HR+/HER2- Breast Cancer: New Perspectives from ELEVATE and ASCO 2026 Supported by Menarini Stemline Dr. Hussam Marashi (SEHA Tawam, Al Ain)		
12:50 - 02:00		Lunch Break / Networking	
SESSION 3: GASTROINTESTINAL ONCOLOGY (02:00- 02:50)			
Moderators: Dr. Aswatha Ramesh (SEHA Tawam, Al Ain) Dr. Emad Dawoud (SEHA Tawam, Al Ain)			
02:00 - 02:10	Abstract 102: Benefit of adjuvant chemotherapy in resected stage I-IV CRC patients based on ctDNA dynamics across two timepoints: Results from GALAXY study. Dr. Dhanaraju Muniswamy (NMC Al Nahda/DIP, Dubai)		
02:10 - 02:20	Abstract LBA3503: BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC). Dr. Syed Monawer Karim (King's Cancer Care Centre, Dubai)		
02:20 - 02:30	Abstract 2502: SWOG S1609 (DART): A phase II basket trial of dual anti-CTLA-4 and anti-PD 1 blockade in rare tumors. Dr. Nouri Bennini (SEHA Tawam, Al Ain)		
02:30 - 02:40	Abstract LBA4000: Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants... Dr. Abdul Rahman El Kinge (NMC Royal, Sharjah)		
02:40 - 02:50	Abstract LBA5: Daraxonrasib, a RAS(ON) multi-selective inhibitor, vs. chemotherapy in previously treated patients with metastatic pancreatic adenocarcinoma (mPDAC): Primary analysis from the phase 3 RASolute 302 study. Dr. Cherian Thampy (NMC, Abu Dhabi)		

**Subject to changes*

SESSION 4: GU, PROSTATE & GYNECOLOGIC ONCOLOGY (02:50 - 05:10)

Moderators: Dr. Nouri Bennini (Tawam, Al Ain) | Dr. Aftab Ahmad Bhatti (Tawam/STMC, Al Ain) | Dr. Thikra Al Safi (Tawam, Al Ain) | Dr. Aly Abdel Razek (GICC) | Dr. Muwafak Salman (Tawam, Al Ain)

02:50 - 03:10	Therapeutic strategies for EC: Current standards and evolving paradigm Supported by GSK Dr. Emad Dawoud (SEHA Tawam, Al Ain)	
03:10 - 03:20	Abstract LBA1: Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs. placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced... Dr. Maha Ebrahim Esmail (Zulekha, Dubai)	
03:20 - 03:30	Abstract 5001: Assessment of the ability of Decipher Prostate Genomic Classifier (DGC) >0.85 to identify patients who benefit from adding docetaxel (DOC) to androgen deprivation therapy (ADT) plus enzalutamide (ENZ). Dr. Mourad Salam (GICC, Abu Dhabi)	
03:30 - 03:40	Abstract 5005: Cognitive effects of darolutamide vs. enzalutamide: Results of ARACOG (AFT-47), a randomized clinical trial from the Alliance for Clinical Trials in Oncology. Dr. Jawaher Ansari (Consultant Medical Oncology, NMC, Dubai)	
03:40 - 04:00	Coffee Break / Networking	
04:00 - 04:20	RLT in Prostate Cancer: Expanding Evidence Across Disease Stages Supported by Novartis Dr. Nouri Bennini (SEHA Tawam, Al Ain)	
04:20 - 04:30	Abstract 108: An AI-based pathology classifier to predict benefit from enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC) from ENZAMET (ANZUP 1304). Dr. Dalia Elshorbagy (SSMC, Abu Dhabi)	
04:30 - 04:40	Abstract 4507: Enfortumab vedotin plus pembrolizumab (EV+P) vs. chemotherapy for previously untreated locally advanced or metastatic urothelial carcinoma (la/ mUC). Dr. Reham Omar (NMC Royal, Sharjah)	
04:40 - 04:50	Abstract 5505: CHRONO: A randomized phase II trial of the chronology of surgery after neoadjuvant chemotherapy for ovarian cancer. Dr. Muhammad Nasim (SEHA Tawam, Al Ain)	
04:50 - 05:00	Abstract 5506: A randomized phase II trial of mirvetuximab soravtansine in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy (MIROVA/AGO-OVAR 2.34). Dr. Muhammad Nasim (SEHA Tawam, Al Ain)	
05:00 - 05:10	Abstract 5517: Effects of short-term fasting compared to free diet in ovarian cancer patients: Results from a two-arm pilot randomized trial. Ms. Ruqaya Suhail Juma Marzouq Alshamsi (SEHA Tawam Hospital, Al Ain)	
05:10	End of Day 1 – Main Program	

**Subject to
changes*

27-28 June 2026

Al Ain Rotana Hotel, Al Ain, UAE.

CONFERENCE PROGRAM

DAY 2



28 June 2026 (Sunday)



09:00 - 04:20

SESSION 5: LUNG CANCER PRACTICE-CHANGING UPDATES (09:00 - 11:50)

Moderators: Dr. Emad Dawoud (SEHA Tawam, Al Ain) | Dr. Mariam Almarashda (SEHA Tawam/STMC, Al Ain) | Dr. Omran El Koha (SEHA Tawam, Al Ain)

09:00 - 09:30	Renewed Hope through long-term outcomes in Alk+ mNSCLC Supported by Pfizer Dr Dina Hamza (Dubai Hospital, Dubai)	
09:30 - 09:40	Abstract LBA3: Event-Free Survival with Adjuvant Selpercatinib in Stage IB-IIIa RET Fusion-Positive NSCLC: Primary Results of the Phase 3 LIBRETTO-432 Trial. Dr. Syed Tirmazy (Dubai Hospital, Dubai)	
09:40 - 09:50	Abstract 8000: Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST). Dr. Almurtaadha Mula (American Hospital, Dubai)	
09:50 - 10:20	Shaping long-term treatment outcomes in the management of EGFRm NSCLC Supported by AstraZeneca Dr. Emad Dawoud (SEHA Tawam, Al Ain)	
10:20 - 10:30	Abstract LBA4: Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non-small cell lung cancer: Overall survival results of the phase 3 HARMONI-6 trial. Dr. Hassan Shahryar (SSMC, Abu Dhabi)	
10:30 - 10:50	Advances of Immunotherapy in management of resectable Non-small Cell Lung Cancer Supported by BMS Dr. Emad Dawoud (SEHA Tawam, Al Ain)	
10:50 - 11:00	Coffee Break / Networking	
11:10 - 11:20	Abstract LBA8500: Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of WU-KONG28. Dr. Mudhasir Ahmad (Lifecare Musaffah, Abu Dhabi)	
11:20 - 11:30	Abstract 8506: Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab as first-line treatment for PD-L1-positive advanced NSCLC. Dr. Diaeddine Trad (SEHA Tawam, Al Ain)	
11:30 - 11:50	Abstract 8613: COPERNICUS, a pragmatic Phase 2b study of first-line (1L) subcutaneous (SC) amivantamab (ami) and lazertinib (laz) with supportive care in EGFR-mutated advanced NSCLC: Early safety results Supported by J&J Dr. Dina Hamza (Dubai Hospital, Dubai)	

*Subject to
changes

SESSION 6: QUALITY, CARE DELIVERY & SUPPORTIVE CARE (11:50 - 12:30)

Moderators: Dr. Nandan Maruti Shanbhag (SEHA Tawam, Al Ain) | Dr. Muhammad Zafar Javed (SEHA Tawam, Al Ain) | Dr. Maroun El Khoury (American Hospital, Dubai)

11:50 - 12:00	Abstract 3143: Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors. Dr. Ram Singarachari (Mediclinic Airport Road Hospital, Abu Dhabi)
12:00 - 12:10	Abstract 11005: Impact of remote therapeutic monitoring with patient-reported outcomes on hospitalization in real-world patients receiving therapy for metastatic solid tumors. Dr. Yaara Alkanash (SEHA Tawam Hospital)
12:10 - 12:30	Session discussion and audience Q&A Session moderators and speakers

12:30 - 02:00 Lunch Break / Networking

SESSION 7: HEMATOLOGIC MALIGNANCIES, MELANOMA & IMMUNOTHERAPY (02:00 – 03:30)

Moderators: Dr. Arif Alam (SEHA Tawam Hospital, Al Ain) : Dr. Salman Ahmed | Dr. Soni Soumian (SEHA Tawam, Al Ain)

02:00 - 02:10	Abstract LBA6500: Selinexor plus ruxolitinib in JAK inhibitor-naïve myelofibrosis: Phase 3 SENTRY trial Dr. Arif Alam (SEHA, Tawam Hospital)
02:10 - 02:20	Abstract LBA7000: frontMIND: Phase 3 study of tafasitamab plus lenalidomide and R-CHOP for patients with newly diagnosed diffuse large B-cell lymphoma. Dr. Hani Yousif Osman (SEHA Tawam Hospital, Al Ain)
02:20 - 02:30	Abstract 11000: The association of GLP-1 receptor agonist use with survival and immune-related adverse events in patients receiving immune checkpoint inhibitors: A multi-institutional real-world analysis. Dr. Najeeb Behzad Mohammed (Zulekha Hospital, Sharjah)
02:30 - 02:40	Abstract LBA7506: Mezigdomide, carfilzomib, and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma: SUCCESSOR-2. Dr. Abdel Rahman Labban (Medeor Hospital, Dubai)
02:40 - 02:50	Abstract 7507: MajesTEC-9: Teclistamab monotherapy vs investigator's choice in relapsed/refractory multiple myeloma. Dr. Amar Lal (SEHA Tawam, Al Ain)
02:50 – 03:00	Abstract LBA9503: Darovasertib in combination with crizotinib versus investigator's choice as first-line treatment for patients with HLA-A2-negative metastatic uveal melanoma: Results from the phase 2/3 OptimUM-02 study. Dr. Roshan Koshy Jacob (NMC Royal, Sharjah)
03:00 - 03:10	Abstract LBA9505: Updated Outcomes from STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial: ECOG-ACRIN EA6174. Dr. Mawada Hussein (Burjeel Medical City, Abu Dhabi)
03:10 - 03:20	Abstract 9518: 3-year landmark overall survival analysis of RP1 plus nivolumab in anti-PD-1-failed melanoma from IGNYTE. Dr. Rajitha Lokadasan (NMC Specialty, Abu Dhabi)
03:20 - 03:30	Session discussion and audience Q&A Session moderators and speakers

03:30 - 03:40 Coffee Break / Networking

**Subject to
changes*

SESSION 8: SARCOMA, CNS & PRECISION THERAPEUTICS (03:40 - 04:20)

Moderators: Dr. Hussam Marashi (SEHA Tawam, Al Ain) | Dr. Mahdi Al-Taher (SEHA Tawam, Al Ain)

03:40 - 03:50	Abstract LBA2: SARC041: Abemaciclib versus placebo in advanced dedifferentiated liposarcoma. Dr. Sonia Otsmane (Burjeel Medical City, Abu Dhabi)
03:50 - 04:00	Abstract 11500: PEAK study of bezuclastinib plus sunitinib vs sunitinib in advanced GIST. Dr. Bharadwaj Ponnada (Zulekha, Dubai)
04:00 - 04:10	Abstract LBA2000: Post-operative stereotactic radiation versus cesium-131 tile-based radiation after resection for newly diagnosed brain metastases. Dr. Nadeem Pervez (Radiation Oncology, UAE)
04:10 - 04:20	Best of ASCO 2026 closing summary Closing Remarks: Dr. Hussam Marashi (SEHA Tawam, Al Ain) Conference Chair :Dr. Khalid Saeed Balaraj (SEHA Tawam, Al Ain)
04:20	End of Conference

**Subject to
changes*